Physician profile
John Sutter
NPI 1861711509
$641.07
in general payments reported to CMS, 2019-2025
15 companies · $16.11 in 2025
The $16.11 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $16.74 · 2021: $41.75 · 2022: $130 · 2023: $299 · 2024: $137 · 2025: $16.11.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $453.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $452.62 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $210.35 | 2022-2025 | Vraylar, Ubrelvy, Qulipta |
| Novo Nordisk INC | $87.21 | 2021-2024 | |
| Pfizer INC. | $59.18 | 2021-2024 | |
| Lilly USA, LLC | $40.95 | 2023-2024 | Mounjaro, Jardiance, Emgality |
| Boehringer Ingelheim Pharmaceuticals, INC. | $35.57 | 2023-2024 | Jardiance, Trijardy Xr, Glyxambi |
| Astrazeneca Pharmaceuticals Lp | $29.49 | 2024 | Farxiga, Airsupra |
| Inspire Medical Systems, INC. | $26.51 | 2023 | Inspire |
| Glaxosmithkline, LLC. | $25.92 | 2023 | Shingrix |
| Janssen Pharmaceuticals, INC | $25.13 | 2024 | Spravato |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $21.56 | 2023 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $18.95 | 2023 | Xifaxan |
| Biohaven Pharmaceutical Holding Company Ltd. | $17.19 | 2022 | |
| Shire North American Group INC | $16.74 | 2019 | |
| Phathom Pharmaceuticals, INC. | $13.87 | 2024 | Voquezna |
| Antares Pharma, INC. | $12.45 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Sutter listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.